CliffBio
small molecule

AKOVAZ

EPHEDRINE SULFATE

Loss of exclusivity—loss of exclusivity
CompanyExela Pharma Sciences Llc →See this company's full patent-cliff portfolio

Drug detail

Brand nameAKOVAZ
Active ingredientEPHEDRINE SULFATE
Strength25MG/5ML (5MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalAugust 2021
Marketing statusRX

More from Exela Pharma Sciences Llc

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.